Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
Paul A. Mahon, Executive Vice President and General Counsel at United Therapeutics Corp (NASDAQ:UTHR), a pharmaceutical company with an $18.1 billion market cap and "EXCELLENT" financial health according to InvestingPro, sold 8,675 shares of common stock on September 4, 2025, at prices ranging from $379.4737 to $396.54, netting $4,237,281. The stock has shown strong momentum, gaining nearly 25% in the past week.
On the same day, Mahon also exercised stock options for 11,000 shares at a price of $135.42, for a total value of $1,489,619. Following these transactions, Mahon directly owns 36,981 shares of United Therapeutics Corp .
The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan.
In other recent news, United Therapeutics announced that its TETON-2 pivotal study of Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint. The study showed that nebulized Tyvaso (treprostinil) Inhalation Solution demonstrated a statistically significant improvement in forced vital capacity (FVC) compared to placebo, with a change of 95.6 mL. Following these positive results, several analyst firms have adjusted their price targets for United Therapeutics. H.C. Wainwright raised its price target to $500, UBS increased it to $560, and Jefferies set a new target of $564, all maintaining a Buy rating on the stock. These adjustments reflect the analysts’ confidence in the potential market impact of Tyvaso in IPF treatment. Additionally, United Therapeutics has expanded its partnership with MannKind Corporation to develop a second dry powder inhalation therapy. This collaboration builds on their previous work, which led to the FDA-approved Tyvaso DPI for pulmonary hypertension. These developments highlight the company’s ongoing efforts to advance its therapeutic offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.